Caribou Biosciences (CRBU) Capital Expenditures (2020 - 2025)
Caribou Biosciences (CRBU) reported Capital Expenditures of -$216000.0 for Q4 2025, down 156.69% year-over-year from $381000.0 in Q4 2024, and down 287.83% on a QoQ basis from $115000.0 in Q3 2025.
Caribou Biosciences (CRBU) has 6 years of Capital Expenditures data on file, last reported at -$216000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 156.69% year-over-year to -$216000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 6811.11% YoY) and the FY2025 annual result came in at $1.4 million, up 80.24% from the prior year.
- Capital Expenditures declined to -$216000.0 in Q4 2025 per CRBU's latest filing, from $115000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.0 million in Q3 2022 and bottomed at -$4.0 million in Q3 2023.
- The 5-year median for Capital Expenditures is $289500.0 (2024), against an average of $307450.0.
- The widest annual swing landed in 2021, when Capital Expenditures surged 6542.86%; it then plunged 607.15% in 2022.
- Tracing CRBU's Capital Expenditures over 5 years: stood at $685000.0 in 2021, then sank by 607.15% to -$3.5 million in 2022, then surged by 103.91% to $136000.0 in 2023, then soared by 180.15% to $381000.0 in 2024, then tumbled by 156.69% to -$216000.0 in 2025.
- Per Business Quant, the three latest CRBU Capital Expenditures figures stand at -$216000.0 (Q4 2025), $115000.0 (Q3 2025), and $1.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -216,000.00 |
| Dec 31, 2025 | -216,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 1.35 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 115,000.00 |
| Mar 31, 2025 | 115,000.00 |
| Dec 31, 2024 | 381,000.00 |
| Dec 31, 2024 | 381,000.00 |
| Sep 30, 2024 | 198,000.00 |
| Sep 30, 2024 | 198,000.00 |
| Jun 30, 2024 | -676,000.00 |
| Jun 30, 2024 | -676,000.00 |
| Mar 31, 2024 | 851,000.00 |
| Mar 31, 2024 | 851,000.00 |
| Dec 31, 2023 | 136,000.00 |
| Dec 31, 2023 | 136,000.00 |
| Sep 30, 2023 | -4.03 Mn |
| Sep 30, 2023 | -4.03 Mn |
| Jun 30, 2023 | 2.87 Mn |
| Jun 30, 2023 | 2.87 Mn |
| Mar 31, 2023 | 1.71 Mn |
| Mar 31, 2023 | 1.71 Mn |
| Dec 31, 2022 | -3.47 Mn |
| Dec 31, 2022 | -3.47 Mn |
| Sep 30, 2022 | 3.99 Mn |
| Sep 30, 2022 | 3.99 Mn |
| Jun 30, 2022 | -274,000.00 |
| Jun 30, 2022 | -274,000.00 |
| Mar 31, 2022 | 981,000.00 |
| Mar 31, 2022 | 981,000.00 |
| Dec 31, 2021 | 685,000.00 |
| Dec 31, 2021 | 685,000.00 |
| Sep 30, 2021 | 930,000.00 |
| Sep 30, 2021 | 930,000.00 |
| Jun 30, 2021 | 484,000.00 |
| Jun 30, 2021 | 484,000.00 |
| Mar 31, 2021 | 22,000.00 |
| Mar 31, 2021 | 22,000.00 |
| Dec 31, 2020 | 27,000.00 |
| Dec 31, 2020 | 27,000.00 |
| Sep 30, 2020 | 14,000.00 |
| Sep 30, 2020 | 14,000.00 |